# Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

> **NCT05469022** · PHASE2 · RECRUITING · sponsor: **Konkuk University Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Neoadjuvant lazertinib

## Key facts

- **NCT ID:** NCT05469022
- **Lead sponsor:** Konkuk University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-19
- **Primary completion:** 2024-05-19
- **Final completion:** 2027-05-19
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469022, "Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05469022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*